Biosimilars Policy Roundup for March 2023—Podcast Edition
On this episode of Not So Different, we discuss some of the global biosimilar policy news that came out during the month of March, including a new bill in Congress and 2 Canadian jurisdictions implementing switching policies.
On this episode of Not So Different, we discuss some of the global biosimilar policy news that came out during the month of March, including a new bill in Congress and 2 Canadian jurisdictions implementing switching policies.
Show notes
Canadian Province Newfoundland and Labrador Adds Biosimilar Switching Policy
Yukon Becomes Tenth Canadian Jurisdiction to Add Biosimilars Switching Policy
Policy Recommendations for Improving Biosimilar Uptake in Belgium
Researchers Recommend Improvements for China’s Biosimilar Regulatory Policies
The Increasing Access to Biosimilars Act of 2023 Introduced to Congress
Published Data Coupled With Real-world Evidence Show Safety of Biosimilar-to-Biosimilar Switching
Uptake Barriers Will Deter Future Competitors From Investing in Biosimilars, Julie Reed Warns
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
BioRationality: FDA Launches a New Opportunity to Remove Redundant Trials of Biosimilars
November 6th 2023The FDA introduced a plan to improve clinical trials, including a provision to possibly eliminate clinical efficacy testing for biologic products, which evidence has suggested may not be necessary, according to Sarfaraz K. Niazi, PhD.
